De Novo Pharmaceuticals
Cambridge
About De Novo Pharmaceuticals
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2001)
- Website: denovopharma.com
- Phone: +44 0 1223 488888
Industries & Categories
Health Care, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/de-novo-pharmaceuticals-717970 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.